Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
NetherlandsIPO:
23 December 2020Website:
http://www.pharming.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
PHAR Latest News
Pharming Group N.V. (NASDAQ: PHAR) will be hosting its Q1 2024 Earnings Conference Call on May 8, 2024 at 7:30 AM ET. The company's Executive Director and CEO, Sijmen de Vries, along with Chief Commercial Officer Stephen Toor, Chief Medical Officer Anurag Relan, and Chief Financial Officer Jeroen Wakkerman will be participating. Conference call participants include Christian Glennie from Stifel, Sushila Hernandez from Van Lanschot Kempen, and Joe Pantginis from H.C.
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average.
Pharming Group NV is a biotechnology firm known for its unique approach to addressing rare and genetic diseases. The company's financials show growth in revenue, primarily driven by strong sales of their leading therapy, Ruconest. Pharming's expansion into organ transplantation fields adds a new dimension to their growth prospects, but challenges remain in gaining acceptance and assessing the impact on their income.
LEIDEN, The Netherlands , Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September: 2023 Wells Fargo Healthcare Conference, Boston, September 6-8 Sijmen de Vries, Chief Executive Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Thursday, September 7 at 16:30 ET/22:30 CET.
Pharming Group N.V. (NASDAQ:PHAR ) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - Executive Director and Chief Executive Officer Anurag Relan - Chief Medical Officer Stephen Toor - Chief Commercial Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Christian Glennie - Stifel Joseph Pantginis - H.C.
Pharming Group N.V. (OTCPK:PHGUF) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - CEO Anurag Relan - CMO Stephen Toor - CCO Jeroen Wakkerman - CFO Conference Call Participants Christian Glennie - Stifel Joe Pantginis - H.C.
LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.
Pharming Group N.V. (OTCPK:PHGUF) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Sijmen de Vries – Chief Executive Officer Anurag Relan – Chief Medical Officer Stephen Toor – Chief Commercial Officer Jeroen Wakkerman – Chief Financial Officer Conference Call Participants Alistair Campbell – RBC Sushila Hernandez – VLK Simon Scholes – First Berlin Sijmen de Vries Good morning or good afternoon, ladies and gentlemen.
Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume.
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
What type of business is Pharming Group NV?
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
What sector is Pharming Group NV in?
Pharming Group NV is in the Healthcare sector
What industry is Pharming Group NV in?
Pharming Group NV is in the Biotechnology industry
What country is Pharming Group NV from?
Pharming Group NV is headquartered in Netherlands
When did Pharming Group NV go public?
Pharming Group NV initial public offering (IPO) was on 23 December 2020
What is Pharming Group NV website?
https://www.pharming.com
Is Pharming Group NV in the S&P 500?
No, Pharming Group NV is not included in the S&P 500 index
Is Pharming Group NV in the NASDAQ 100?
No, Pharming Group NV is not included in the NASDAQ 100 index
Is Pharming Group NV in the Dow Jones?
No, Pharming Group NV is not included in the Dow Jones index
When does Pharming Group NV report earnings?
The next expected earnings date for Pharming Group NV is 01 August 2024